COMMUNIQUÉS West-GlobeNewswire

Matinas BioPharma Reports 2017 Financial Results
26/03/2018
BEDMINSTER, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications [...]
Emergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth Strategy
26/03/2018
GAITHERSBURG, Md., March 26, 2018 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS ) today announced executive management changes that continue to align its organizational structure to its long-term strategy [...]
Intercept to Present at Upcoming Conference
26/03/2018
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT ), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non- [...]
Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction
26/03/2018
Verification & Validation (“V&V”) “head-to-head” data exceeds target concordance for blood grouping Overall concordance for antigen typing – 99.8%, demonstrating robustness of the MosaiQ platform Completion of [...]
Eyenovia Appoints Three Industry Veterans to Board of Directors
26/03/2018
NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN ), a clinical stage biopharmaceutical company developing a pipeline of ophthalmology products utilizing its patented piezo-print technology to [...]
AnaptysBio Announces Positive Top-Line Proof-of-Concept Data For ANB020 In Moderate-to-Severe Baseline Adult Peanut Allergy Patients
26/03/2018
46% of adult peanut allergy patients with moderate-to-severe baseline symptoms tolerated 500mg cumulative peanut challenge at 14 days after a single dose of ANB020 compared to zero percent dosed with placebo Concomitant [...]
Quotient Limited Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer
26/03/2018
JERSEY, Channel Islands, March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT ), a commercial-stage diagnostics company, today announced the retirement of Paul Cowan as its Chairman and Chief Executive [...]
Sol-Gel Technologies Ltd. Availability of Its Annual Report on Form 20-F Through Its Website
26/03/2018
NESS ZIONA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL ), a clinical-stage dermatology company, announced today that it filed its Annual Report for 2017 on Form 20-F, containing [...]
DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering
26/03/2018
Montrouge, France, March 26, 2018 DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering DBV Technologies (the "Company") (Euronext: DBV - ISIN: FR0010417345 - Nasdaq [...]
DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de son offre globale
26/03/2018
Montrouge, France, le 26 Mars (22h00 CEST), 2018 DBV Technologies annonce le règlement-livraison des actions ordinaires supplémentaires au titre de l'exercice de la totalité de l'option de surallocation dans le cadre de [...]
argenx announces Annual General Meeting of Shareholders on May 8, 2018
26/03/2018
March 26, 2018 Breda, the Netherlands - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe [...]
MacroGenics Announces Proposed Public Offering of Common Stock
26/03/2018
ROCKVILLE, MD, March 26, 2018 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for [...]
Profound Medical Corp. Announces Fourth Quarter and Full Year 2017 Financial Results
26/03/2018
TORONTO, March 26, 2018 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX-V: PRN ) (OTCQX:PRFMF) (“Profound” or the “Company”), the only company to provide a therapeutics platform that provides the precision of real-time [...]
CRISPR Therapeutics Announces the Retirement of Tyler Dylan-Hyde and Appointment of Shelby Walker as Head of Intellectual Property
26/03/2018
ZUG, Switzerland and CAMBRIDGE, Mass., March 26, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP ), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, [...]
Data From TOPACIO Trial Reported at SGO Demonstrates Compelling Clinical Activity of ZEJULA in Combination With an Anti-PD-1 Antibody in Patients With Platinum Resistant/Refractory Ovarian Cancer
26/03/2018
Efficacy of niraparib in combination with an anti-PD-1 mAb surpasses historical efficacy benchmarks for PD-1 or PARP monotherapies in difficult-to-treat types of ovarian cancer, regardless of biomarker status Potential [...]
Stage 3 Meaningful Use Certification Achieved by PracticeSuite EHR
26/03/2018
SILICON VALLEY, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Cloud based medical office platform PracticeSuite announced today it has achieved Stage 3 Meaningful Use certification of its electronic health record (EHR) [...]
Medical Cannabis Protections Extended to 46 States
26/03/2018
ALBUQUERQUE, New Mexico, March 26, 2018 (GLOBE NEWSWIRE) -- Medical cannabis patients and businesses are protected from federal intervention after President Trump signed the country’s new spending bill into law Friday. [...]
MJ Biotech Inc. Q & A Update w/ Doctor Interview
26/03/2018
CHEYENNE, Wyo., March 26, 2018 (GLOBE NEWSWIRE) -- MJ Biotech, Inc. (FKA Michael James Enterprises, Inc.) (OTC:MJTV) announced that the interview with Maxine Pierson CEO of MJ Biotech, Inc and Fernando Lopez COO of MJ [...]
Ossur Hf : Transactions in relation to share buyback program
26/03/2018
Announcement no. 23/2018 Reykjavik, 26 March 2018 Transactions in relation to share buyback program On 5 March 2018, Össur hf. initiated a share buy-back program, see Company announcement no. 16/2018. The purpose of the [...]

Pages